Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neogenix Oncology has received additional $244,479.24 grant for the therapeutic development of the NPC-1C antibody.
Subscribe to our email newsletter
The grant which is awarded under the Qualifying Therapeutic Discovery Project Program (QTDP) to Neogenix is totaled up to $733,437.74.
The company’s NPC-1C (Ensituximab) monoclonal antibody is currently in Phase I multi-center clinical trial for advanced colorectal and pancreatic cancer.
Neogenix CEO Philip Arlen said that this additional federal grant will be extremely beneficial to the company, helping to move their product development forward while continuing the clinical trial of NPC-1C monoclonal antibody for colorectal and pancreatic cancer.